Heechung J Yang

US Patent:

49544527, Sep 4, 1990

Filed:

Jul 9, 1987

Appl. No.:

7/072084

Inventors:

David A. Yost - Round Lake Park IL
John C. Russell - Greenfield WI
Heechung Yang - Green Oaks IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

G01N 33551
G01N 33566
G01N 33543
G01N 33536

US Classification:

436524

Abstract:

A method of performing a diagnostic immunoassay utilizing colloidal non-metal particles having conjugated thereto a binding component capable of specifically recognizing an analyte to be determined. After reaction of the sample and colloidal non-metal particles, the presence or amount of analyte/colloidal non-metal particle complexes are determined by optical analysis as a measure of the amount of analyte in the sample. The method can be utilized for the specific detection of numerous analytes and is sensitive and has a wide detection range.

US Patent:

57027277, Dec 30, 1997

Filed:

Mar 6, 1995

Appl. No.:

8/409613

Inventors:

Alfred A. Amkraut - Palo Alto CA
Heechung Yang - Palo Alto CA

Assignee:

Alza Corporation - Palo Alto CA

International Classification:

A61K 914
A61K 951
A61K 964
A61K 3800

US Classification:

424491

Abstract:

Compositions and methods for the oral administration of drugs and other active agents are provided. The compositions comprise an active agent carrier particle attached to a binding moiety which binds specifically to a target molecule present on the surface of a mammalian enterocyte. The binding moiety binds to the target molecule with a binding affinity or avidity sufficient to initiate endocytosis or phagocytosis of the particulate active agent carrier so that the carrier will be absorbed by the enterocyte. The active agent will then be released from the carrier to the host's systemic circulation. In this way, degradation of degradation-sensitive drugs, such as polypeptides, in the intestines can be avoided while absorption of proteins and polypeptides from the intestinal tract is increased.

US Patent:

60081872, Dec 28, 1999

Filed:

May 12, 1995

Appl. No.:

8/440270

Inventors:

Heechung Yang - Palo Alto CA
Vu Anh Nguyen - San Jose CA
Liang C. Dong - Mountain View CA
Patrick S. L. Wong - Palo Alto CA

Assignee:

Alza Corporation - Palo Alto CA

International Classification:

A61K 3800

US Classification:

514 2

Abstract:

The present invention is directed to a pharmaceutical formulation of a therapeutic polypeptide together with a permeation-enhancing mixture of sodium salicylate and an oil to provide enhanced absorption of the polypeptide through the wall of the gastrointestinal tract, and particularly of the colon, after oral administration, the amount of oil being from about 10 wt % to about 30 wt %, preferably from about 15 wt % to about 25 wt %, of the total formulation and the amount of sodium salicylate being from about 70 wt % to about 90 wt %, preferably from about 75 wt % to about 85 wt %, of the total formulation. The polypeptide may be non-lyophilized. The pharmaceutical formulation is characterized as a solid, which provides a convenient and improved format for handling and storage and for the preparation of oral dosage forms (such as pills, capsules and delivery vessels) containing a homogeneous mixture of ingredients.

US Patent:

54242894, Jun 13, 1995

Filed:

Jul 30, 1993

Appl. No.:

8/099884

Inventors:

Heechung Yang - Palo Alto CA
Vu A. Nguyen - San Jose CA
Liang C. Dong - Mountain View CA
Patrick S.-L. Wong - Palo Alto CA

Assignee:

Alza Corporation - Palo Alto CA

International Classification:

A61K 3800

US Classification:

514 12

Abstract:

The present invention is directed to a pharmaceutical formulation of a therapeutic polypeptide together with a permeation-enhancing mixture of sodium salicylate and an oil to provide enhanced absorption of the polypeptide through the wall of the gastrointestinal tract, and particularly of the colon, after oral administration, the amount of oil being from about 10 wt % to about 30 wt %, preferably from about 15 wt % to about 25 wt %, of the total formulation and the amount of sodium salicylate being from about 70 wt % to about 90 wt %, preferably from about 75 wt % to about 85 wt %, of the total formulation. The polypeptide may be non-lyophilized. The pharmaceutical formulation is characterized as a solid, which provides a convenient and improved format for handling and storage and for the preparation of oral dosage forms (such as pills, capsules and delivery vessels) containing a homogeneous mixture of ingredients.

US Patent:

56207085, Apr 15, 1997

Filed:

Feb 1, 1995

Appl. No.:

8/382476

Inventors:

Alfred A. Amkraut - Palo Alto CA
Heechung Yang - Palo Alto CA

Assignee:

ALZA Corporation - Palo Alto CA

International Classification:

A61K 914
A61K 918
A61K 4748
A61K 3800

US Classification:

424491

Abstract:

Compositions and methods for the oral administration of drugs and other active agents are provided. The compositions comprise an active agent carrier particle attached to a binding moiety which binds specifically to a target molecule present on the surface of a mammalian enterocyte. The binding moiety binds to the target molecule with a binding affinity or avidity sufficient to initiate endocytosis or phagocytosis of the particulate active agent carrier so that the carrier will be absorbed by the enterocyte. The active agent will then be released from the carrier to the host's systemic circulation. In this way, degradation of degradation-sensitive drugs, such as polypeptides, in the intestines can be avoided while absorption of proteins and polypeptides from the intestinal tract is increased.

US Patent:

58176241, Oct 6, 1998

Filed:

Jun 5, 1995

Appl. No.:

8/465661

Inventors:

Heechung Yang - Palo Alto CA
Robert E. Myrback - Milpitas CA
Deborah A. Fox - Oakton VA
Vu Anh Nguyen - San Jose CA

Assignee:

Alza Corporation - Palo Alto CA

International Classification:

A61K 3827
A61K 3828
A61K 3104

US Classification:

514 3

Abstract:

The present invention is directed to a pharmaceutical formulation of a therapeutic polypeptide together with a permeation-enhancing mixture of sodium 3-nitrobenzoate and an oil to provide enhanced absorption of the polypeptide through the wall of the gastrointestinal tract, and particularly of the colon, after oral administration.